Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?

Eur Urol. 2016 Nov;70(5):898-899. doi: 10.1016/j.eururo.2016.06.013. Epub 2016 Jun 20.

Authors

Orazio Caffo¹, Nima Sharifi²

Affiliations

¹ Medical Oncology Department, Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.
² Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

PMID: 27339836
DOI: 10.1016/j.eururo.2016.06.013

No abstract available

Publication types

Letter

MeSH terms

Abiraterone Acetate
Androstenes / pharmacology*
Humans
Male
Prostatic Neoplasms, Castration-Resistant
Substance Withdrawal Syndrome

Substances

Androstenes
Abiraterone Acetate
abiraterone